Liver Cancer pp 285-293 | Cite as

Adjuvant Therapy for Prevention of Liver Metastases

  • Howard W. Bruckner
Part of the Developments in Oncology book series (DION, volume 30)


A number of diseases can be successfully treated with perisurgical adjuvant therapy. In the case of gastrointestinal tumors, the best tested of the treatments involve the use of systemic therapy in combination with radiotherapy. The status of adjuvant therapy for adults is an area of active investigation. There are no firmly established treatments of choice.


Gastric Cancer Rectal Cancer Liver Metastasis Adjuvant Therapy Systemic Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davis HL, Kisner DL. Analysis of adjuvant therapy in large bowel cancer. Cancer Clin Trials 1:273–287, 1978.PubMedGoogle Scholar
  2. 2.
    Higgins GA, Amadeo JH, McEchinney J, McCaughan JJ, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and Methyl-CCNU following resection for carcinoma of the large bowel. Cancer 53:5311–5318, 1984.CrossRefGoogle Scholar
  3. 3.
    The Gastrointestinal Tumor Study Group. Adjuvant therapy of adenocarcinoma of the colon following clinically curative resection: An interim report from the Gastrointestinal Tumor Study Group. In Adjuvant Therapy of Cancer III, Jones, SE, Salmon, SE (eds). New York: Grune & Statton, 1981, pp. 527–537.Google Scholar
  4. 4.
    Mansour EG, MacIntyre JM, Johnson R, Lerner HJ, Muggia FM. Adjuvant studies in colorectal carcinoma: experience of the Eastern Cooperative Oncology Group (ECOG). Preliminary report. In Progress and Prospects in the Treatment of Gastrointestinal Tumors, Gerard A, (ed). Oxford, NY: Pergamon Press, 1981, pp. 68–75.Google Scholar
  5. 5.
    Taylor I, Brooman P, Rowling JT. Adjuvant perfusion in colorectal cancer: initial results of a clinical trial. Br Med J 2:1320–1322, 1977.PubMedCrossRefGoogle Scholar
  6. 6.
    Taylor I, Cooke T, Machin D, Harmon M. Adjuvant therapy of colorectal cancer with portal vein cytotoxic perfusion. Fourth International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, March 21–24, 1984.Google Scholar
  7. 7.
    Gastrointestinal Tumor Study Group. Adjuvant therapy of cancer—results of a prospectively randomized trial. N E J Med 310:737–743, 1984.CrossRefGoogle Scholar
  8. 8.
    Kaplan RS, Childs DS, Learning RL, for the Gastrointestinal Group: Protocol GI 6179: adjuvant combination therapy of resectable adenocarcinoma of the colon with whole-liver irradiation and 5-fluorouracil, August 1979.Google Scholar
  9. 9.
    Mavligit GM, Gutterman JV, Macally MA, Burgess MA, McBride CM, Jubert A, Hersh EM. Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes’ Class C). Prolongation of disease free interval and survival. Cancer 40:2726–2730, 1977.Google Scholar
  10. 10.
    Speyer JL, Sugarbaker PH, Collins JM, et al. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922, 1981.PubMedGoogle Scholar
  11. 11.
    Bruckner HW, Stablein DM, for the Gastrointestinal Tumor Study Group. Sites of treatment failure: Gastrointestinal Tumor Study Group analysis of gastric, pancreatic, and colorectal trials. Cancer Treatment Symposia 2:199–210, 1983.Google Scholar
  12. 12.
    Findlay IG, McArdle. Occult hepatic metastases in colon cancer. Gastroenterol 85:596–599, 1983.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston/Dordrecht/Lancaster 1985

Authors and Affiliations

  • Howard W. Bruckner

There are no affiliations available

Personalised recommendations